Jonathan D Santoro1, Michael Waltz2, Greg Aaen2, Anita Belman2, Leslie Benson2, Mark Gorman2, Manu S Goyal2, Jennifer S Graves2, Yolanda Harris2, Lauren Krupp2, Timothy Lotze2, Soe Mar2, Manikum Moodley2, Jayne Ness2, Mary Rensel2, Moses Rodriguez2, Teri Schreiner2, Jan-Mendelt Tillema2, Emmanuelle Waubant2, Bianca Weinstock-Guttman2, Brigitte F Hurtubise2, Shelly Roalstad2, John Rose2, T Charles Casper2, Tanuja Chitnis1. 1. From Partners Pediatric Multiple Sclerosis Center (J.D.S., T.C.), Massachusetts General Hospital; Harvard Medical School (J.D.S.), Boston, MA; Pediatric Multiple Sclerosis and Related Disorders Program at Boston Children's Hospital (J.D.S., L.B., M.G.), MA; Children's Hospital Los Angeles (J.D.S.); Keck School of Medicine at the University of Southern California (J.D.S.), Los Angeles; Data Coordinating and Analysis Center (M.W., S.R., J.R., T.C.C.), University of Utah, Salt Lake City; Pediatric Multiple Sclerosis Center (G.A.), Loma Linda University Children's Hospital, CA; Pediatric MS Center at NYU Langone Health (A.B., L.K.), New York, NY; Washington University (M.S.G., S.M.), St. Louis, MO; Pediatric Multiple Sclerosis Center (J.S.G.), University of California San Diego; UAB Center for Pediatric-Onset Demyelinating Disease (Y.H., J.N.), University of Alabama at Birmingham; The Blue Bird Circle Clinic for Multiple Sclerosis (T.L.), Texas Children's Hospital, Baylor College of Medicine, Houston; Mellen Center for Multiple Sclerosis (M.M., M. Rensel), Cleveland Clinic, OH; Mayo Clinic Pediatric Multiple Sclerosis Center (M. Rodriguez, J.-M.T.), Mayo Clinic, Rochester, MN; Rocky Mountain Multiple Sclerosis Center (T.S.), Children's Hospital Colorado, University of Colorado at Denver, Aurora; Pediatric Multiple Sclerosis Center (E.W.), University of California San Francisco; Jacobs Pediatric Multiple Sclerosis Center (B.W.-G.), State University of New York at Buffalo; and Department of Neurology (B.F.H.), Stanford University School of Medicine, Palo Alto, CA. jdsantoro@chla.usc.edu tchitnis@partners.org. 2. From Partners Pediatric Multiple Sclerosis Center (J.D.S., T.C.), Massachusetts General Hospital; Harvard Medical School (J.D.S.), Boston, MA; Pediatric Multiple Sclerosis and Related Disorders Program at Boston Children's Hospital (J.D.S., L.B., M.G.), MA; Children's Hospital Los Angeles (J.D.S.); Keck School of Medicine at the University of Southern California (J.D.S.), Los Angeles; Data Coordinating and Analysis Center (M.W., S.R., J.R., T.C.C.), University of Utah, Salt Lake City; Pediatric Multiple Sclerosis Center (G.A.), Loma Linda University Children's Hospital, CA; Pediatric MS Center at NYU Langone Health (A.B., L.K.), New York, NY; Washington University (M.S.G., S.M.), St. Louis, MO; Pediatric Multiple Sclerosis Center (J.S.G.), University of California San Diego; UAB Center for Pediatric-Onset Demyelinating Disease (Y.H., J.N.), University of Alabama at Birmingham; The Blue Bird Circle Clinic for Multiple Sclerosis (T.L.), Texas Children's Hospital, Baylor College of Medicine, Houston; Mellen Center for Multiple Sclerosis (M.M., M. Rensel), Cleveland Clinic, OH; Mayo Clinic Pediatric Multiple Sclerosis Center (M. Rodriguez, J.-M.T.), Mayo Clinic, Rochester, MN; Rocky Mountain Multiple Sclerosis Center (T.S.), Children's Hospital Colorado, University of Colorado at Denver, Aurora; Pediatric Multiple Sclerosis Center (E.W.), University of California San Francisco; Jacobs Pediatric Multiple Sclerosis Center (B.W.-G.), State University of New York at Buffalo; and Department of Neurology (B.F.H.), Stanford University School of Medicine, Palo Alto, CA.
Abstract
OBJECTIVE: To characterize disease severity and distribution of disability in pediatric-onset multiple sclerosis (POMS) and to develop an optimized modeling scale for measuring disability, we performed a multicenter retrospective analysis of disability scores in 873 persons with POMS over time and compared this to previously published data in adults with multiple sclerosis (MS). METHODS: This was a retrospective analysis of prospectively collected data collected from 12 centers of the US Network of Pediatric MS Centers. Patients were stratified by the number of years from first symptoms of MS to Expanded Disability Status Scale (EDSS) assessment and an MS severity score (Pediatric Multiple Sclerosis Severity Score [Ped-MSSS]) was calculated per criteria developed by Roxburgh et al. in 2005. RESULTS: In total, 873 patients were evaluated. In our cohort, 52%, 19.4%, and 1.5% of all patients at any time point reached an EDSS of 2.0, 3.0, and 6.0. Comparison of our Ped-MSSS scores and previously published adult Multiple Sclerosis Severity Scores (MSSS) showed slower progression of Ped-MSSS with increasing gaps between higher EDSS score and years after diagnosis. Decile scores in our POMS cohort for EDSS of 2.0, 3.0, and 6.0 were 8.00/9.46/9.94, 7.86/9.39/9.91, and 7.32/9.01/9.86 at 2, 5, and 10 years, respectively. Notable predictors of disease progression in both EDSS and Ped-MSSS models were ever having a motor relapse and EDSS at year 1. Symbol Digit Modalities Test (SDMT) scores were inversely correlated with duration of disease activity and cerebral functional score. CONCLUSIONS: Persons with POMS exhibit lower EDSS scores compared to persons with adult-onset MS. Use of a Ped-MSSS model may provide an alternative to EDSS scoring in clinical assessment of disease severity and disability accrual.
OBJECTIVE: To characterize disease severity and distribution of disability in pediatric-onset multiple sclerosis (POMS) and to develop an optimized modeling scale for measuring disability, we performed a multicenter retrospective analysis of disability scores in 873 persons with POMS over time and compared this to previously published data in adults with multiple sclerosis (MS). METHODS: This was a retrospective analysis of prospectively collected data collected from 12 centers of the US Network of Pediatric MS Centers. Patients were stratified by the number of years from first symptoms of MS to Expanded Disability Status Scale (EDSS) assessment and an MS severity score (Pediatric Multiple Sclerosis Severity Score [Ped-MSSS]) was calculated per criteria developed by Roxburgh et al. in 2005. RESULTS: In total, 873 patients were evaluated. In our cohort, 52%, 19.4%, and 1.5% of all patients at any time point reached an EDSS of 2.0, 3.0, and 6.0. Comparison of our Ped-MSSS scores and previously published adult Multiple Sclerosis Severity Scores (MSSS) showed slower progression of Ped-MSSS with increasing gaps between higher EDSS score and years after diagnosis. Decile scores in our POMS cohort for EDSS of 2.0, 3.0, and 6.0 were 8.00/9.46/9.94, 7.86/9.39/9.91, and 7.32/9.01/9.86 at 2, 5, and 10 years, respectively. Notable predictors of disease progression in both EDSS and Ped-MSSS models were ever having a motor relapse and EDSS at year 1. Symbol Digit Modalities Test (SDMT) scores were inversely correlated with duration of disease activity and cerebral functional score. CONCLUSIONS: Persons with POMS exhibit lower EDSS scores compared to persons with adult-onset MS. Use of a Ped-MSSS model may provide an alternative to EDSS scoring in clinical assessment of disease severity and disability accrual.
Authors: L A Benson; B C Healy; M P Gorman; N F Baruch; T Gholipour; A Musallam; T Chitnis Journal: Mult Scler Relat Disord Date: 2013-07-12 Impact factor: 4.339
Authors: Alan J Thompson; Brenda L Banwell; Frederik Barkhof; William M Carroll; Timothy Coetzee; Giancarlo Comi; Jorge Correale; Franz Fazekas; Massimo Filippi; Mark S Freedman; Kazuo Fujihara; Steven L Galetta; Hans Peter Hartung; Ludwig Kappos; Fred D Lublin; Ruth Ann Marrie; Aaron E Miller; David H Miller; Xavier Montalban; Ellen M Mowry; Per Soelberg Sorensen; Mar Tintoré; Anthony L Traboulsee; Maria Trojano; Bernard M J Uitdehaag; Sandra Vukusic; Emmanuelle Waubant; Brian G Weinshenker; Stephen C Reingold; Jeffrey A Cohen Journal: Lancet Neurol Date: 2017-12-21 Impact factor: 44.182
Authors: Nadine Akbar; Alessio Signori; Maria Pia Amato; Maria Pia Sormani; Emilio Portaccio; Claudia Niccolai; Benedetta Goretti; Christine Till; Brenda Banwell Journal: Dev Neuropsychol Date: 2017-09-05 Impact factor: 2.253
Authors: Ilya Kister; Eric Chamot; Gary Cutter; Tamar E Bacon; Vilija G Jokubaitis; Stella E Hughes; Orla M Gray; Maria Trojano; Guillermo Izquierdo; Francois Grand'Maison; Pierre Duquette; Alessandra Lugaresi; Pierre Grammond; Cavit Boz; Raymond Hupperts; Thor Petersen; Giorgio Giuliani; Celia Oreja-Guevara; Gerardo Iuliano; Jeannette Lechner-Scott; Roberto Bergamaschi; Maria Edite Rio; Freek Verheul; Marcela Fiol; Vincent Van Pesch; Mark Slee; Helmut Butzkueven; Joseph Herbert Journal: J Neurol Sci Date: 2012-04-14 Impact factor: 3.181
Authors: W S MacAllister; A L Belman; M Milazzo; D M Weisbrot; C Christodoulou; W F Scherl; T E Preston; C Cianciulli; L B Krupp Journal: Neurology Date: 2005-04-26 Impact factor: 9.910
Authors: Tanuja Chitnis; Douglas L Arnold; Brenda Banwell; Wolfgang Brück; Angelo Ghezzi; Gavin Giovannoni; Benjamin Greenberg; Lauren Krupp; Kevin Rostásy; Marc Tardieu; Emmanuelle Waubant; Jerry S Wolinsky; Amit Bar-Or; Tracy Stites; Yu Chen; Norman Putzki; Martin Merschhemke; Jutta Gärtner Journal: N Engl J Med Date: 2018-09-13 Impact factor: 91.245
Authors: Ali Manouchehrinia; Helga Westerlind; Elaine Kingwell; Feng Zhu; Robert Carruthers; Ryan Ramanujam; Maria Ban; Anna Glaser; Stephen Sawcer; Helen Tremlett; Jan Hillert Journal: Mult Scler Date: 2017-02-03 Impact factor: 6.312
Authors: Jonathan D Santoro; Laura E Saucier; Runi Tanna; Sarah E Wiegand; Dania Pagarkar; Adam F Tempchin; Mellad Khoshnood; Nusrat Ahsan; Keith Van Haren Journal: Front Pediatr Date: 2021-12-01 Impact factor: 3.418